НИКОТИНЗАМЕСТИТЕЛЬНАЯ ТЕРАПИЯ ТАБАЧНОЙ ЗАВИСИМОСТИ В ПРОФИЛАКТИКЕ КАРДИОРЕСПИРАТОРНЫХ ЗАБОЛЕВАНИЙ

Потребление табака является серьезной медико-социальной проблемой в России и одним из основных факторов риска кардиореспираторных заболеваний. Прекращение курения — самая эффективная и экономичная мера предупреждения сердечно-сосудистых и респираторных заболеваний и риска смерти от этих болезней. Помощь курящим пациентам в отказе от потребления табака затрудняется из-за наличия у большинства из них никотиновой зависимости. Никотинзаместительная терапия (НЗТ) направлена на преодоление табачной зависимости, смягчения симптомов отмены, связанных с прекращением курения. НЗТ удваивает шансы курящих пациентов в успешном преодолении курения, и в силу доказанной безопасности среди существующих современных фармакологических средств является методом выбора для лечения табакокурения у пациентов с сердечно-сосудистыми и респираторными заболеваниями вне обострения. Сочетание быстро и медленно действующих форм лекарственных препаратов для НЗТ повышает эффективность метода, помогая купировать сиюминутную тягу к курению и зависимость в долгосрочной перспективе. НЗТ может успешно применяться для помощи пациентам стационаров, при реализации положений нового Федерального «антитабачного» закона в медицинских учреждениях.

никотиновая зависимость, потребление табака, курение, лечение табачной зависимости, никотинзаместительная терапия, профилактика сердечно-сосудистых заболевании, профилактика респираторных болезней

1. WHO report on the global tobacco epidemic. Geneva: WHO; 2011. Available at: http://whqlib- doc.who.int/publications/2011/9789240687813_eng.pdf. Date of access: 25.05.2013.

2. Lopez A. Smoking and death in Russia. Tobacco Control 1998; 7:3–4.

3. World Health Organization - NCD Country Profiles. Geneva: WHO; 2011. Available at: http://www.who.int/nmh/countries/rus_en.pdf. Date of access: 25.05.2013.

4. Wilhelmsen L. Coronary heart disease: Epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242–9.

5. Shalnova SA, Deev AD, Oganov RG. Factors affecting the mortality from cardiovascular diseases in russian population. Kardiovaskulyarnaya Terapia I Profilaktika 2005; 4(1):4-9. Russian (Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная Терапия и Профилактика 2005; 4(1): 4–9.

6. U.S. Department of Health and Human Services. The Health Consequences of Smoking. A Report of the Surgeon General; 2004. Available at: 25.05.2013. Date of access: 25.05.2013.

7. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004;1:CD003041.

8. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750–8.

9. Rivers JT, White HD, Cross DB, et al. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking. J Am Coll Cardiol 1990; 16: 340–8.

10. Balfour D., Benowitz N., Fagerstrom K., et al. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. Eur Heart J 2000; 21: 438–45.

11. Iestra JA, Kromhout D, van der Schouw YT, et al. Effect Size Estimates of Lifestyle and Dietary Changes on All-Cause Mortality in Coronary Artery Disease Patients A systematic review. Circulation 2005; 112: 924–34.

12. Anthonisen NR, Skeans MA, Wise RA, et al. Lung Health Study Research Group The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142(4):233–9.

13. Au DH, Bryson CL, Chien JW, et al. The Effects of Smoking Cessation on the Risk of Chronic Obstructi Pulmonary Disease Exacerbations. J Gen Intern Med 2009; 24(4): 457–63.

14. Hughes JR, Gulliver SB, Fenwick JW, et al. Smoking cessation among self-quitters. Health Psychol 1992; 11: 331–334.

15. Rigotti NA, Singer DE, Mulley AG Jr, Thibault GE. Smoking cessation following admission to a coronary care unit. J Gen Intern Med 1991; 6:305–311.

16. Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365–70.

17. Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract 2002; 52: 132–4.

18. European Guidelines on cardiovascular disease prevention in clinical practice (version2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–701.

19. Tønnesen P., Carrozzi L., Fagerstrom K.O. et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29: 390–417.

20. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 2008;168:1950–60.

21. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106–10.

22. International Classification of Diseases. Version: 2010. Available at: http://apps.who.int/classifications/icd10/browse/2010/en. Date of access: 25.05.2013.

23. Giovino GA, Henningfield JE, Tomar SL, et al. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995; 17: 48–65.

24. Benowitz N.L. Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment. The American Journal of Medicine 2008; 121(4A):S3–S10.

25. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001; 70:439 – 46.

26. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445–9.

27. Benowitz NL. Nicotine addiction. Prim Care 1999; 26: 611–31.

28. Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev 2005; 48: 420–37.

29. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905–8.

30. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006; 63: 907–15.

31. Hughes JR. Clinical significance of tobacco withdrawal. Nicotine Tob Res2006; 8: 153–6.

32. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008;3:CD006103.

33. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221–9.

34. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359–66.

35. Levshin VF, Slepchenko NI, Radkevich NV. Randomised controlled trial of effectiveness of Tabex in Tobacco dependence Treatement. Medicinskiy Vestnik 2009;33:502-3. Russian (Левшин В.Ф., Слепченко Н.И., Радкевич Н.В. Рандомизированное контролируемое исследование эффективности препарата Табекс при лечении табачной зависимости. Медицинский Вестник 2009;33: 502–3).

36. West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193–200 .

37. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146.

38. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012;11:CD000146.

39. Tran K, Asakawa K, Cimon K, et al. Pharmacologic-based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses. CADTH Technol Overv 2012;2(3):e2303.

40. Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J 2005;149:565–72.

41. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196–203.

42. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008 Sep;53(9):1217–22.

43. Tonnesen R., Paoletti P., Gustavsson G., et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur Respir J 1999; 13: 238–46.

44. Molyneux A, Lewis S, Leivers U, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax 2003;58(6):484–8.

45. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010; 8:8.

46. Ottervanger JP, Festen JM, de Vries AG, Stricker BH. Acute myocardial infarction while using the nicotine patch. Chest 1995;107:1765–6.

47. Ropchan GV, Sanfilippo AJ, Ford SE. Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. Can J Cardiol 1997; 13:525–8.

48. Van der Klauw MM, Van Hillo B, Van den Berg WH, et al. Vasculitis attributed to the nicotine patch (Nicotinell). Br J Dermatol 1996;134:361–4.

49. Dacosta A, Guy JM, Tardy B, et al. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J 1993;14:1709–11.

50. Pierce JR Jr. Stroke following application of a nicotine patch [letter]. Ann Pharmacother 1994;28:402.

51. Warner JG Jr, Little WC. Myocardial infarction in a patient who smoked while wearing a nicotine patch [letter]. Ann Intern Med 1994;120:695.

52. Riche G, Nighoghossian N, Trouillas P. Intracerebral haematoma after application of nicotine patch [let- ter]. Lancet 1995;346:777–8.

53. Mathew TP, Herity NA. Acute myocardial infarction soon after nicotine replacement therapy [letter]. QJM 2001;94:503–4.

54. Ford CL, Zlabek JA. Nicotine Replacement Therapy and Cardiovascular Disease. Mayo Clin Proc 2005;80(5):652–6.

55. Working Group for the Study of Transdermal Nicotine in Patients With Coronary Artery Disease. Nico- tine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994;154:989– 95.

56. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792–8.

57. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998;18:297–308.

58. Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001;37:1297–1302.

59. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of theAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:671–719.